– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated ...

Good morning. I would like to introduce Ms. Amy Bachrodt, Senior Vice President of Finance at Maze Therapeutics. Please go ahead. Good morning, everyone, and thank you for joining us today for Maze's ...

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid ...

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 -- Maze Therapeutics, Inc. a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic ...

Five solar power plants are set to be connected to the national energy grid for the first time in Georgia’s history, marking a historic step for the country’s renewable energy development. Georgian ...

Maze Therapeutics on Tuesday filed plans for an initial public offering that could become the biotechnology sector’s first of the year, depending on how quickly the deal comes together. If Maze is ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 ...

Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in ...